Table 6

Circulating miRNA in patients with pancreatic lesions

miRNA	Material	Lesions vs controls	miRNA status	References
miR-21	Plasma	PC vs healthy subjects	Upregulated	69
	Plasma	PC vs healthy subjects	Upregulated	77
	Serum	PDAC vs CP vs healthy subjects	Upregulated	78
	Serum	PC vs healthy subjects	Upregulated	74
miR-221	Plasma	PC vs benign lesions vs healthy controls	Upregulated	71
miR-221	Serum	PC vs CRC	Upregulated	79
miR-155	Plasma	PC vs healthy subjects	Upregulated	77
	Plasma	PC vs CP	Upregulated	79
	Serum	PDAC and CP vs healthy subjects	Upregulated	78
	Pancreatic juice, bile, plasma	PDAC vs CP	Upregulated	61
	Pancreatic juice	PC vs CP vs healthy subjects	Upregulated	53
miR-210	Plasma	PC vs healthy subjects	Upregulated	77
	Plasma	PC vs healthy subjects	Upregulated	70
		PDAC vs non-pancreatic non-healthy controls	Upregulated	62
miR-196	Plasma	PC vs healthy subjects	Upregulated	77
	Plasma	PC vs CP	Upregulated	73
	Serum	PDAC and CP vs healthy subjects	Upregulated	78
miR-10	Serum	PC vs healthy subjects	Upregulated	79
miR-10	Plasma	PDAC vs control normal subjects	Upregulated	94

Only miRNA observed deregulated in at least two papers have been reported.
CP, chronic pancreatitis; CRC, colorectal carcinoma; PC, pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma.